EYPT
EyePoint Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.12B
5Y Perf.+55.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EYPT vs KALA
Revenue, margins, valuation, and 5-year total return — side by side.
KALA
KALA BIO, Inc.
Biotechnology
Market Cap$618K
5Y Perf.-100.0%
EYPT vs KALA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EYPT | KALA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.12B | $618K |
| Revenue (TTM) | $31M | $254K |
| Net Income (TTM) | $-232M | $-36M |
| Gross Margin | 93.4% | -3.1% |
| Operating Margin | -7.8% | -150.6% |
| Total Debt | $21M | $32M |
| Cash & Equiv. | $102M | $51M |
EYPT vs KALA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EYPT
KALA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| EyePoint Pharmaceut… (EYPT) | 100 | 155.9 | +55.9% |
| KALA BIO, Inc. (KALA) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EYPT vs KALA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EYPT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. KALA BIO, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
EYPT
EyePoint Pharmaceuticals, Inc.
The Income Pick
EYPT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.20
- -55.2% 10Y total return vs KALA's -100.0%
- Lower volatility, beta 1.20, Low D/E 6.8%, current ratio 8.88x
Best for: income & stability and long-term compounding
KALA
KALA BIO, Inc.
The Growth Play
KALA is the clearest fit if your priority is growth exposure.
- Rev growth 262.9%, EPS growth 59.8%
- 262.9% revenue growth vs EYPT's -27.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KALA | 262.9% revenue growth vs EYPT's -27.5% |
| Quality / Margins | EYPT | -7.4% margin vs KALA's -141.1% |
| Stability / Safety | EYPT | Beta 1.20 vs KALA's 2.09, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | EYPT | +120.2% vs KALA's -97.6% |
| Efficiency (ROA) | EYPT | -72.5% ROA vs KALA's -143.2% |
EYPT vs KALA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
EYPT vs KALA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEYPTLAGGINGKALA
KALAKALA BIO, Inc.
0leads
EYPTEyePoint Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs KALAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EYPT4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EYPT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
EYPT6/6
Risk & VolatilityBeta, volatility, and downside exposure
EYPT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EYPT leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
EYPT is the larger business by revenue, generating $31M annually — 123.5x KALA's $254,000. EYPT is the more profitable business, keeping -7.4% of every revenue dollar as net income compared to KALA's -141.1%.
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $31M | $254,000 |
| EBITDAEarnings before interest/tax | -$242M | -$38M |
| Net IncomeAfter-tax profit | -$232M | -$36M |
| Free Cash FlowCash after capex | -$243M | -$32M |
| Gross MarginGross profit ÷ Revenue | +93.4% | -3.1% |
| Operating MarginEBIT ÷ Revenue | -7.8% | -150.6% |
| Net MarginNet income ÷ Revenue | -7.4% | -141.1% |
| FCF MarginFCF ÷ Revenue | -7.8% | -126.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -94.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -26.6% | +44.6% |
EYPT leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — EYPT and KALA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Market CapShares × price | $1.1B | $617,676 |
| Enterprise ValueMkt cap + debt − cash | $1.0B | -$18M |
| Trailing P/EPrice ÷ TTM EPS | -4.23x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 35.82x | — |
| Price / BookPrice ÷ Book value/share | 3.21x | 0.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — EYPT and KALA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
EYPT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
EYPT delivers a -88.3% return on equity — every $100 of shareholder capital generates $-88 in annual profit, vs $-4 for KALA. EYPT carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to KALA's 2.62x.
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -88.3% | -3.9% |
| ROA (TTM)Return on assets | -72.5% | -143.2% |
| ROICReturn on invested capital | -75.5% | — |
| ROCEReturn on capital employed | -69.9% | -95.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.07x | 2.62x |
| Net DebtTotal debt minus cash | -$81M | -$19M |
| Cash & Equiv.Liquid assets | $102M | $51M |
| Total DebtShort + long-term debt | $21M | $32M |
| Interest CoverageEBIT ÷ Interest expense | -7376.79x | -6.92x |
EYPT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
EYPT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EYPT five years ago would be worth $13,768 today (with dividends reinvested), compared to $3 for KALA. Over the past 12 months, EYPT leads with a +120.2% total return vs KALA's -97.6%. The 3-year compound annual growth rate (CAGR) favors EYPT at 27.5% vs KALA's -82.6% — a key indicator of consistent wealth creation.
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.3% | -86.6% |
| 1-Year ReturnPast 12 months | +120.2% | -97.6% |
| 3-Year ReturnCumulative with dividends | +107.3% | -99.5% |
| 5-Year ReturnCumulative with dividends | +37.7% | -100.0% |
| 10-Year ReturnCumulative with dividends | -55.2% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +27.5% | -82.6% |
EYPT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
EYPT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EYPT is the less volatile stock with a 1.20 beta — it tends to amplify market swings less than KALA's 2.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EYPT currently trades 70.2% from its 52-week high vs KALA's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 2.09x |
| 52-Week HighHighest price in past year | $19.11 | $20.60 |
| 52-Week LowLowest price in past year | $5.30 | $0.08 |
| % of 52W HighCurrent price vs 52-week peak | +70.2% | +0.4% |
| RSI (14)Momentum oscillator 0–100 | 44.3 | 30.1 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 9.2M |
EYPT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EYPT as "Buy" and KALA as "Buy". Consensus price targets imply 21861.5% upside for KALA (target: $18) vs 179.6% for EYPT (target: $38).
| Metric | EYPTEyePoint Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $37.50 | $18.25 |
| # AnalystsCovering analysts | 18 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
EYPT leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallEyePoint Pharmaceuticals, I… (EYPT)Leads 4 of 6 categories
Loading custom metrics...
EYPT vs KALA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EYPT or KALA a better buy right now?
Analysts rate EyePoint Pharmaceuticals, Inc.
(EYPT) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EYPT or KALA?
Over the past 5 years, EyePoint Pharmaceuticals, Inc.
(EYPT) delivered a total return of +37. 7%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: EYPT returned -55. 2% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EYPT or KALA?
By beta (market sensitivity over 5 years), EyePoint Pharmaceuticals, Inc.
(EYPT) is the lower-risk stock at 1. 20β versus KALA BIO, Inc. 's 2. 09β — meaning KALA is approximately 75% more volatile than EYPT relative to the S&P 500. On balance sheet safety, EyePoint Pharmaceuticals, Inc. (EYPT) carries a lower debt/equity ratio of 7% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EYPT or KALA?
On earnings-per-share growth, the picture is similar: KALA BIO, Inc.
grew EPS 59. 8% year-over-year, compared to -36. 6% for EyePoint Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EYPT or KALA?
EyePoint Pharmaceuticals, Inc.
(EYPT) is the more profitable company, earning -739. 4% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -739. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EYPT leads at -776. 0% versus -150. 6% for KALA. At the gross margin level — before operating expenses — EYPT leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — EYPT or KALA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is EYPT or KALA better for a retirement portfolio?
For long-horizon retirement investors, EyePoint Pharmaceuticals, Inc.
(EYPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EYPT: -55. 2%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EYPT and KALA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.